Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Prebiotic205 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00025 | 35251100 | Front Plant Sci | Raffinose Family Oligosaccharides: Friend or Foe for Human and Plant Health? | 2022 | Details |
| A00113 | 35216439 | Int J Mol Sci | Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-.Leiden Mice. | 2022 | Details |
| A00392 | 35103461 | Minerva Endocrinol (Torino) | Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. | 2022 | Details |
| A00515 | 35055177 | Int J Mol Sci | Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. | 2022 | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | 2021 | Details |
| A00758 | 34978141 | Obes Rev | Human microbiome and metabolic health: An overview of systematic reviews. | 2022 | Details |
| A01446 | 34742934 | Arch Biochem Biophys | The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. | 2021 | Details |
| A01474 | 34734433 | J Gastroenterol Hepatol | New perspective on fecal microbiota transplantation in liver diseases. | 2022 | Details |
| A01475 | 34734369 | J Gastrointest Surg | The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. | 2021 | Details |
| A01731 | 34634561 | Biomed Pharmacother | Jaboticaba (Myrciaria jaboticaba) powder consumption improves the metabolic profile and regulates gut microbiome composition in high-fat diet-fed mice. | 2021 | Details |
| A01838 | 34598315 | Immun Inflamm Dis | Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. | 2021 | Details |
| A01921 | 34561722 | Eur J Nutr | Effects of β-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice. | 2021 | Details |
| A02013 | 34530928 | Microbiome | Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. | 2021 | Details |
| A02045 | 34521466 | Trials | Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. | 2021 | Details |
| A02082 | 34511051 | Benef Microbes | Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | 2021 | Details |
| A02267 | 34441497 | Foods | Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. | 2021 | Details |
| A02471 | 34360773 | Int J Mol Sci | Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. | 2021 | Details |
| A02491 | 34355155 | JHEP Rep | A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients. | 2021 | Details |
| A02533 | 34338703 | Food Funct | Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. | 2021 | Details |
| A02552 | 34330514 | Clin Nutr ESPEN | Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. | 2021 | Details |
| A02694 | 34280304 | Cochrane Database Syst Rev | Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. | 2021 | Details |
| A02733 | 34267042 | Curr Opin Infect Dis | The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. | 2021 | Details |
| A02766 | 34251802 | J Agric Food Chem | Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis. | 2021 | Details |
| A02798 | 34235516 | Food Funct | The interaction between gut microbiota and flavonoid extract from Smilax glabra Roxb. and its potent alleviation of fatty liver. | 2021 | Details |
| A02865 | 34212214 | Inflamm Res | Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. | 2021 | Details |
| A02892 | 34204274 | Int J Mol Sci | Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. | 2021 | Details |
| A02973 | 34177920 | Front Immunol | Prebiotic Inulin and Sodium Butyrate Attenuate Obesity-Induced Intestinal Barrier Dysfunction by Induction of Antimicrobial Peptides. | 2021 | Details |
| A02977 | 34176456 | Curr Pharm Des | Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03114 | 34125646 | Gut Microbes | Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. | 2021 | Details |
| A03181 | 34097961 | Int J Biol Macromol | A homogeneous polysaccharide from Lycium barbarum: Structural characterizations, anti-obesity effects and impacts on gut microbiota. | 2021 | Details |
| A03206 | 34090052 | Biomed Pharmacother | Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. | 2021 | Details |
| A03378 | 34025071 | World J Gastroenterol | Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis. | 2021 | Details |
| A03462 | 33992651 | Int J Biol Macromol | Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. | 2021 | Details |
| A03463 | 33992352 | Food Res Int | Caffeic acid prevents non-alcoholic fatty liver disease induced by a high-fat diet through gut microbiota modulation in mice. | 2021 | Details |
| A03556 | 33957682 | Semin Liver Dis | New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03579 | 33946843 | Microorganisms | Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. | 2021 | Details |
| A03645 | 33921370 | Int J Environ Res Public Health | Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering. | 2021 | Details |
| A03732 | 33885128 | Food Funct | Modulation of the fecal microbiome and metabolome by resistant dextrin ameliorates hepatic steatosis and mitochondrial abnormalities in mice. | 2021 | Details |
| A04200 | 33718398 | Front Med (Lausanne) | Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. | 2021 | Details |
| A04278 | 33679403 | Front Pharmacol | Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis. | 2021 | Details |
| A04600 | 33567710 | Int J Environ Res Public Health | Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. | 2021 | Details |
| A04617 | 33561650 | Biomed Pharmacother | The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. | 2021 | Details |
| A04632 | 33557031 | Life (Basel) | Adiposity in Depression or Depression in Adiposity? The Role of Immune-Inflammatory-Microbial Overlap. | 2021 | Details |
| A04649 | 33552218 | Evid Based Complement Alternat Med | Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review. | 2021 | Details |
| A04668 | 33546191 | Biomedicines | Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. | 2021 | Details |
| A04774 | 33510856 | Comput Struct Biotechnol J | Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. | 2020 | Details |
| A05088 | 33382431 | J Nutr | Polylactose Exhibits Prebiotic Activity and Reduces Adiposity and Nonalcoholic Fatty Liver Disease in Rats Fed a High-Fat Diet. | 2021 | Details |
| A05227 | 33331485 | Arq Gastroenterol | GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). | 2021 | Details |
| A05243 | 33327227 | Medicine (Baltimore) | Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria. | 2020 | Details |
| A05614 | 33187278 | Nutrients | The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A05786 | 33117316 | Front Microbiol | Microbial Metabolites: Critical Regulators in NAFLD. | 2020 | Details |
| A05829 | 33105554 | Nutrients | Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. | 2020 | Details |
| A05981 | 33053631 | Nutrients | Microbiota, Fiber, and NAFLD: Is There Any Connection? | 2020 | Details |
| A05985 | 33050862 | Curr Pharm Biotechnol | Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review. | 2022 | Details |
| A06233 | 32960625 | Nutr Hosp | [Effectiveness of hydroxycinamates and beta-glucans as dietary tools against obesity and its associated dysfunctions, and their application as nutraceuticals]. | 2020 | Details |
| A06423 | 32885440 | J Food Sci | Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. | 2020 | Details |
| A06474 | 32865911 | Crit Rev Oncog | Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression. | 2020 | Details |
| A06628 | 32801031 | J Nutr Biochem | Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. | 2020 | Details |
| A06688 | 32780531 | Mol Nutr Food Res | Lactobacillus rhamnosus GG and Oat Beta-Glucan Regulated Fatty Acid Profiles along the Gut-Liver-Brain Axis of Mice Fed with High Fat Diet and Demonstrated Antioxidant and Anti-Inflammatory Potentials. | 2020 | Details |
| A06810 | 32738185 | Mol Nutr Food Res | The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A06866 | 32717871 | Int J Mol Sci | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. | 2020 | Details |
| A06952 | 32688217 | J Nutr Biochem | Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota. | 2020 | Details |
| A06993 | 32668632 | Int J Mol Sci | Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? | 2020 | Details |
| A07357 | 32526796 | Mol Nutr Food Res | Dietary Fiber from Oat and Rye Brans Ameliorate Western Diet-Induced Body Weight Gain and Hepatic Inflammation by the Modulation of Short-Chain Fatty Acids, Bile Acids, and Tryptophan Metabolism. | 2020 | Details |
| A07581 | 32436410 | Nutr Cancer | Combined Amelioration of Prebiotic Resveratrol and Probiotic Bifidobacteria on Obesity and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07686 | 32390701 | World J Gastroenterol | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. | 2020 | Details |
| A08143 | 32230987 | Nutrients | Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). | 2020 | Details |
| A08601 | 32044317 | Gastroenterology | Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? | 2020 | Details |
| A08776 | 31987796 | Gastroenterology | Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A09184 | 31845054 | J Gastroenterol | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. | 2019 | Details |
| A09227 | 31828683 | Eur J Clin Microbiol Infect Dis | Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. | 2019 | Details |
| A09316 | 31793324 | Nutr Hosp | Immunonutritional contribution of gut microbiota to fatty liver disease. | 2020 | Details |
| A09447 | 31745030 | Indian J Med Microbiol | Gut microbiota and its mysteries. | 2020 | Details |
| A09892 | 31572482 | Arch Med Sci | Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. | 2019 | Details |
| A10220 | 31425956 | Diabetes Metab Syndr | A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. | 2019 | Details |
| A10364 | 31373710 | Aliment Pharmacol Ther | Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. | 2019 | Details |
| A10368 | 31372513 | Commun Biol | Ability of prebiotic polysaccharides to activate a HIF1α-antimicrobial peptide axis determines liver injury risk in zebrafish. | 2019 | Details |
| A10726 | 31219825 | Curr Opin Clin Nutr Metab Care | Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? | 2019 | Details |
| A10757 | 31208043 | Nutrients | Dietary Fiber in Bilberry Ameliorates Pre-Obesity Events in Rats by Regulating Lipid Depot, Cecal Short-Chain Fatty Acid Formation and Microbiota Composition. | 2019 | Details |
| A10817 | 31175629 | Curr Obes Rep | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. | 2019 | Details |
| A10835 | 31165837 | Food Funct | Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. | 2019 | Details |
| A10891 | 31137547 | Medicina (Kaunas) | Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10936 | 31114130 | World J Gastroenterol | Microbial metabolites in non-alcoholic fatty liver disease. | 2019 | Details |
| A11112 | 31036494 | Ann Hepatol | Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). | 2019 | Details |
| A11579 | 30832423 | Microorganisms | Microbial Population Changes and Their Relationship with Human Health and Disease. | 2019 | Details |
| A11629 | 32461811 | Liver Res | The role of gut microbiota in liver disease development and treatment. | 2019 | Details |
| A11686 | 30791767 | Expert Rev Gastroenterol Hepatol | Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. | 2019 | Details |
| A11912 | 30683985 | Cell Mol Life Sci | The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). | 2019 | Details |
| A11922 | 30680920 | Mol Nutr Food Res | Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. | 2019 | Details |
| A11983 | 30658519 | Int J Mol Sci | Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. | 2019 | Details |
| A12006 | 30648978 | Holist Nurs Pract | Traditional Chinese Medicine and Intestinal Microbiota: A Complementary and Integrative Health Approach to Ameliorate Obesity-Related Diseases. | 2020 | Details |
| A12040 | 30628563 | Proc Nutr Soc | Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. | 2019 | Details |
| A12061 | 30618824 | Front Physiol | Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A12117 | 32864300 | Curr Pharmacol Rep | Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health. | 2019 | Details |
| A12278 | 30537110 | Mol Nutr Food Res | Combination of Whole Grapeseed Flour and Newly Isolated Kefir Lactic Acid Bacteria Reduces High-Fat-Induced Hepatic Steatosis. | 2018 | Details |
| A12583 | 30377993 | J Microbiol | Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. | 2018 | Details |
| A12746 | 30306296 | Eur J Nutr | Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. | 2018 | Details |
| A12749 | 30304749 | Z Gastroenterol | [Comparison of a commercially available, formula-based nutritional therapy enriched with oats fiber with a non-formula isocaloric therapy to treat non-alcoholic fatty liver disease (NAFLD) - a randomized, controlled intervention trial]. | 2018 | Details |
| A12812 | 30272851 | Asia Pac J Clin Nutr | Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease. | 2019 | Details |
| A13021 | 30178233 | Front Med | Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. | 2018 | Details |